TerminatedPhase 2NCT02609048
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Pol F Boudes, M.D.Gilead Sciences
- Intervention
- Placebo Comparator(drug)
- Enrollment
- 41 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2015 – 2016
Study locations (30)
- Mayo Clinic of Arizona, Phoenix, Arizona, United States
- University of California, Davis Medical Center, Sacramento, California, United States
- University of Florida, Gainesville, Florida, United States
- University of Miami, Center for Liver Diseases, Miami, Florida, United States
- Norman Gitlin, MD, Atlanta, Georgia, United States
- Digestive Helathcare of Georgia, Atlanta, Georgia, United States
- Indiana University Hospital - Clinical Research Center, Indianapolis, Indiana, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Gastroenterology Associates of Western Michigan, PLC, d.b.a. West Michigan Clinical Research, Wyoming, Michigan, United States
- Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States
- St. Louis University School of Medicine, St Louis, Missouri, United States
- University of Nebraska Medical Center / The Nebraska Medical Center, Omaha, Nebraska, United States
- North Shore-Long Island Jewish Health System / Division of Gastroenterology, Manhasset, New York, United States
- NYU Langone Medical Center, New York, New York, United States
- Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02609048 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta